Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

HIV and kidney diseases: 35 years of history and consequences.

Campos P, Ortiz A, Soto K.

Clin Kidney J. 2016 Dec;9(6):772-781. Review.

2.

A Review of Management of Inflammation in the HIV Population.

Slim J, Saling CF.

Biomed Res Int. 2016;2016:3420638. Review.

3.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondi A, Costarelli S, Valsecchi MG, Torti C, Gori A; Italian MASTER cohort..

PLoS One. 2016 Sep 15;11(9):e0162320. doi: 10.1371/journal.pone.0162320.

4.

The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney Disease.

Zsengellér ZK, Rosen S.

J Histochem Cytochem. 2016 Sep;64(9):546-55. doi: 10.1369/0022155416660291.

PMID:
27578326
5.

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.

Cho H, Cho Y, Cho EJ, Lee JH, Yu SJ, Oh KH, Lee K, Mustika S, Yoon JH, Kim YJ.

Clin Mol Hepatol. 2016 Jun;22(2):286-91. doi: 10.3350/cmh.2015.0066.

6.

HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.

Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella FJ Jr, Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak MG.

Am J Kidney Dis. 2016 Oct;68(4):571-81. doi: 10.1053/j.ajkd.2016.03.430.

PMID:
27287300
7.

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.

Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.

8.

Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men.

Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella F, Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak M.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):177-81. doi: 10.1097/QAI.0000000000001027.

PMID:
27088295
9.

Drug-Induced Metabolic Acidosis.

Pham AQ, Xu LH, Moe OW.

F1000Res. 2015 Dec 16;4. pii: F1000 Faculty Rev-1460. doi: 10.12688/f1000research.7006.1. Review.

10.

Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team..

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-80. doi: 10.1097/QAI.0000000000000868.

PMID:
26914909
11.

Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.

Mugwanya KK, Baeten JM.

Expert Opin Drug Saf. 2016;15(2):265-73. doi: 10.1517/14740338.2016.1128412. Review.

PMID:
26634852
12.

Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.

Baxi SM, Scherzer R, Greenblatt RM, Minkoff H, Sharma A, Cohen M, Young MA, Abraham AG, Shlipak MG; Womenʼs Interagency HIV Study (WIHS)..

AIDS. 2016 Feb 20;30(4):609-18. doi: 10.1097/QAD.0000000000000958.

PMID:
26558723
13.

Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.

Waheed S, Attia D, Estrella MM, Zafar Y, Atta MG, Lucas GM, Fine DM.

Clin Kidney J. 2015 Aug;8(4):420-5. doi: 10.1093/ckj/sfv041.

14.

Renal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.

Romo FT, Aziz M, Livak B, Huesgen E, Colton B, Flanigan TP, Max B, Kessler H.

J AIDS Clin Res. 2014 Nov;5(11). pii: 379.

15.

Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B.

Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, Zhang J.

Medicine (Baltimore). 2015 Apr;94(15):e646. doi: 10.1097/MD.0000000000000646.

16.

Acute kidney injury in patients with human immunodeficiency virus infection.

Prakash J, Gupta T, Prakash S, Rathore SS, Usha, Sunder S.

Indian J Nephrol. 2015 Mar-Apr;25(2):86-90. doi: 10.4103/0971-4065.138696.

17.

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, Baer R, Sevastos J, Abbas R, Boyd MA.

AIDS Res Ther. 2014 Nov 10;11:35. doi: 10.1186/1742-6405-11-35. Review.

18.

Krüppel-like factor 6 regulates mitochondrial function in the kidney.

Mallipattu SK, Horne SJ, D'Agati V, Narla G, Liu R, Frohman MA, Dickman K, Chen EY, Ma'ayan A, Bialkowska AB, Ghaleb AM, Nandan MO, Jain MK, Daehn I, Chuang PY, Yang VW, He JC.

J Clin Invest. 2015 Mar 2;125(3):1347-61. doi: 10.1172/JCI77084.

19.

Drug-induced impairment of renal function.

Pazhayattil GS, Shirali AC.

Int J Nephrol Renovasc Dis. 2014 Dec 12;7:457-68. doi: 10.2147/IJNRD.S39747. Review.

20.

Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team..

JAMA Intern Med. 2015 Feb;175(2):246-54. doi: 10.1001/jamainternmed.2014.6786.

Items per page

Supplemental Content

Support Center